Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Nonaspirin NSAIDs help prevent postcolonoscopy CRC

24 Apr 2020

Use of nonsteroidal anti‐inflammatory drugs (NSAIDs), except aspirin, is associated with a lower risk of colorectal cancer (CRC) after a negative baseline colonoscopy, a recent study reports.

The retrospective study involved a cohort 187,897 patients aged 40 years who underwent colonoscopies (median age at index procedure, 60.6 years; 48.9 percent male). None of the patients had CRC detected within 6 months of index colonoscopy, prior CRC, inflammatory bowel disease and prior colectomy.

There were 21,757 NSAID users (11.6 percent), with a median duration of use of 0.7 years. Fifty-five (0.25 percent) of them developed CRC between 6 and 36 months after index colonoscopy. The resulting 3-year postcolonoscopy (PC)CRC incidence rate was 8.4 per 10,000 person‐years, which was much lower compared with the rate of 16.1 per 10,000 person‐years among NSAID nonusers.

Multivariable Cox proportional analysis confirmed that NSAID use exerted a protective effect on the risk of 3-year PCCRC (adjusted hazard ratio [aHR], 0.54, 95 percent confidence interval [CI], 0.41–0.70) but not on the risk of >3-year PCCRC. The corresponding aHR estimates for proximal and distal cancers were 0.48 (95 percent CI, 0.24–0.95) and 0.55 (95 percent CI, 0.40–0.74).

A duration‐ and frequency-response relationship was seen (ptrend<0.001), such that a longer duration (>1 year; aHR, 0.42, 95 percent CI, 0.26–0.65) and more frequent NSAID use (at least weekly; aHR: 0.46, 95% CI: 0.32‐0.67) conferred greater protection against 3-year PCCRC.

Aspirin, however, provided no risk-reduction benefit (aHR, 1.01, 95 percent CI, 0.80–1.28).

Researchers underscored a need for further investigation to identify the subgroup of patients who will benefit more from NSAIDs, as such drugs are associated with potential adverse effects.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.